Nuvo Research Inc. has just released the newest research associated with its osteoarthritis drug Pennsaid. This phase 2 study revealed that Pennsaid can lead patients to suffer from the rare and potentially fatal skin disease Stevens-Johnson syndrome (SJS) and its more lethal form, Toxic Epidermal Necrolysis (TENS).
The study, conducted by Covidien, was based on information gathered through research of twice-daily administration of Pennsaid Viscous Solution. The gel helps arthritis patients with pain and inflammation, particularly of the knee.
“We are pleased with the top-line results of this Phase 2 clinical trial for Pennsaid Viscous Solution,” Dr. Bradley S. Galer, president, pain group of Nuvo Research, said. “We look forward to receiving the detailed results from this study in the future and working with Covidien to obtain FDA approval for Pennsaid Viscous Solution.”
This double-blind study took four weeks to complete and pitted Pennsaid against a placebo. The research gathered from 259 patients proved that the gel works as a pain fighter. The most common side effects associated with the drug was dryness of the skin in the area that the gel was applied to. However, the report also lists the risk of patients developing SJS and TENS. The report’s warning states, “Anaphylactoid reactions may occur in patients without prior exposure to Pennsaid. NSAIDs can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TENS), which can be fatal.” Pennsaid is a non-steroidal anti-inflammatory drug (NSAID); most NSAIDs have been linked to SJS and TENS.
If you or a loved one develop SJS or TENS as a result of using Pennsaid, contact SJS attorney Greg Jones today for a free consultation. I am experienced at fighting SJS lawsuits and may be able to help you recover money for your injuries.